231 related articles for article (PubMed ID: 21621871)
1. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures.
Tong J; Sun X; Cheng H; Zhao D; Ma J; Zhen Q; Cao Y; Zhu H; Bai J
Lung Cancer; 2011 Nov; 74(2):155-63. PubMed ID: 21621871
[TBL] [Abstract][Full Text] [Related]
2. VEGF-C in non-small cell lung cancer: meta-analysis.
Jiang H; Shao W; Zhao W
Clin Chim Acta; 2014 Jan; 427():94-9. PubMed ID: 24144865
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
[TBL] [Abstract][Full Text] [Related]
4. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer.
Cheng YL; Lee SC; Harn HJ; Chen CJ; Chang YC; Chen JC; Yu CP
Eur J Cardiothorac Surg; 2003 Feb; 23(2):221-8. PubMed ID: 12559346
[TBL] [Abstract][Full Text] [Related]
5. Cox-2 in non-small cell lung cancer: a meta-analysis.
Jiang H; Wang J; Zhao W
Clin Chim Acta; 2013 Apr; 419():26-32. PubMed ID: 23384501
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma.
Taga S; Osaki T; Ohgami A; Imoto H; Yoshimatsu T; Yoshino I; Yano K; Nakanishi R; Ichiyoshi Y; Yasumoto K
Cancer; 1997 Aug; 80(3):389-95. PubMed ID: 9241072
[TBL] [Abstract][Full Text] [Related]
7. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis.
Meert AP; Martin B; Delmotte P; Berghmans T; Lafitte JJ; Mascaux C; Paesmans M; Steels E; Verdebout JM; Sculier JP
Eur Respir J; 2002 Oct; 20(4):975-81. PubMed ID: 12412692
[TBL] [Abstract][Full Text] [Related]
8. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures.
Fan J; Wang L; Jiang GN; He WX; Ding JA
Lung Cancer; 2008 Jul; 61(1):91-6. PubMed ID: 18192073
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis.
Zhang J; Gu Y; Liu X; Rao X; Huang G; Ouyang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32696952
[TBL] [Abstract][Full Text] [Related]
10. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients.
Su CY; Chang YC; Chan YC; Lin TC; Huang MS; Yang CJ; Hsiao M
Eur J Surg Oncol; 2014 Sep; 40(9):1143-50. PubMed ID: 24969958
[TBL] [Abstract][Full Text] [Related]
11. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
Brambilla E; Moro D; Gazzeri S; Brambilla C
J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
[TBL] [Abstract][Full Text] [Related]
12. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
Berghmans T; Dusart M; Paesmans M; Hossein-Foucher C; Buvat I; Castaigne C; Scherpereel A; Mascaux C; Moreau M; Roelandts M; Alard S; Meert AP; Patz EF; Lafitte JJ; Sculier JP;
J Thorac Oncol; 2008 Jan; 3(1):6-12. PubMed ID: 18166834
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.
Luo Z; Wu RR; Lv L; Li P; Zhang LY; Hao QL; Li W
Int J Clin Exp Pathol; 2014; 7(7):3632-46. PubMed ID: 25120740
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
16. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis.
Martin B; Paesmans M; Berghmans T; Branle F; Ghisdal L; Mascaux C; Meert AP; Steels E; Vallot F; Verdebout JM; Lafitte JJ; Sculier JP
Br J Cancer; 2003 Jul; 89(1):55-64. PubMed ID: 12838300
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
18. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.
Steels E; Paesmans M; Berghmans T; Branle F; Lemaitre F; Mascaux C; Meert AP; Vallot F; Lafitte JJ; Sculier JP
Eur Respir J; 2001 Oct; 18(4):705-19. PubMed ID: 11716177
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
Yang SL; Ren QG; Wen L; Hu JL
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
